Navigation Links
New Clinical Study Shows Masimo PVI(TM) Accurately Predicts Fluid Responsiveness in the ICU
Date:3/31/2009

First Study to Expand PVI Utility Beyond the OR Presented at the 29th International Symposium on Intensive Care and Emergency Medicine in Brussels

IRVINE, Calif., March 31 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that a new independent clinical study demonstrates Masimo PVI to be an "accurate index of fluid responsiveness" for critical care patients in the intensive care unit (ICU).(1) The study, presented at the 29th International Symposium on Intensive Care and Emergency Medicine on March 25, 2009, in Brussels, Belgium, is the first to show the potential value of Masimo PVI to predict fluid responsiveness beyond the operating room (OR) into the ICU.

Critically-ill patients are at great risk for volume depletion. Fluid administration is critical to optimizing oxygen delivery to organs and tissues, but giving too much fluid can induce life-threatening adverse effects. Therefore, parameters that aid clinicians in fluid management decisions may help improve patient outcomes. The most validated predictor of fluid responsiveness is pulse pressure variation (¿PP). However, this parameter requires an invasive arterial pressure catheter, which is not appropriate for all patients, or special software, which is not available in all monitoring systems. Masimo PVI is not only noninvasive, enabling easy application on almost any patient, but is also easily obtained from existing or field upgradable Masimo Rainbow SET(R) pulse oximeters and sensors that are already being used to monitor SpO2 and pulse rate.

In the study, Marc Feissel, MD, and colleagues at Le Centre Hospitalier Belfort-Montbeliard (CHBM) in Belfort, France, along with a team of researchers from Assistance Publique-Hop
'/>"/>

SOURCE Masimo
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray
2. New Discoveries on a Fingertip Test for Screening Silent Heart Disease Promising Results of Recent Clinical Studies to be Presented during the 2009 American College of Cardiology Conference, March 29th - April 1st in Orlando
3. Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure
4. Collexis Connects Biomedical Researchers and Clinical Scientists with the Collexis Expert Platform for Translational Research
5. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
6. Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
7. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
8. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
9. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
10. Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace
11. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... PDS, a leader in providing smart...ty, announces Pajama Pathology®, evolutionizin...ame ‘gold standard’ software used by 8...ld, but on a ‘cost per slide’ basis. ...EB) November 30, 2009 -- PDS has announced another...
(Date:11/30/2009)... , AMSTERDAM, Novemb...d,s,leading publisher of scientific, medical and t...major re-launch of Embase, its comprehensive biome... records from more than 7,000,active, peer reviewe...y role in the advancement of new biomedical,and ph...
(Date:11/27/2009)... A mechanised blue dye test alte...ackaging quality assurance one step closer for pha...t leak testing machine developed by Sepha for ...talled in several local and global pharma-companie...ss quality assurance and productivity improvements...
(Date:11/25/2009)... , ,, BOCA RATON, Fla., No...s been a painful year. Not so for BodyLogicMD. Th...expert physicians specializing exclusively in medi...n the number of physicians in its network si...d is in progress to add more physician-owned cente...
Breaking Biology Technology:Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 4
...esistance,Exerciser has successfully accomplished ...training market into the respiratory therapy marke...xpand-A-Lung, Inc., and,inventor of the most compa...his product for athletes seeking a pocket size por...ity for endurance fitness training., *(PHOTO 72d...
...umans, EGG HARBOR TOWNSHIP, N.J., Jan. 28 Availa...titute of Homeopathy, U.S.A. Division,brings Gemmo... medical and,homeopathic practitioners for a low-i...wpoint Plant stem cell therapy is more advantageou...associated with Human stem cells.,Human stem cells...
...est PharmaTech Inc.,("Quest" or the "Company") tod...search agreement with the BC Cancer Agency (the "B...atment of lung cancer. The,potential treatment wil...2, with various immunotherapeutic agents. Research...ment the therapeutic effects of,immunomodulators s...
Other Biology Technology:It's Good News for The Lungs! 2Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 2Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 3
(Date:11/30/2009)...mber 2009 print issue of The FASEB Journal could...ir fertility that women have had since the 1960s. ... androgenic hormones work in the testis to control...opens a promising avenue for the development of "t...o those who cannot have children because of low sp...
(Date:11/26/2009)...ost distinctive residents. ,Everyone wants to unde...s Michelle McComb from Florida Atlantic University...aps their visual field has been enhanced by their ...excellent stereovision and depth perception. Howev... thought on this theory. In 1942, G. Walls specula...
(Date:11/26/2009)...tries has shown that closing schools in the event ...nificant role in reducing illness transmission. Re...Infectious Diseases compared opportunities for in...ing that they were reduced when schools are shut. ..., Belgium, led a team of European researchers in u...
Breaking Biology News(10 mins):Wide heads give hammerheads exceptional stereo view 2School closure could reduce swine flu transmission by 21 percent 2Ellis Island Event Celebrates Life and Liberty After Cancer 56863 1Ellis Island Event Celebrates Life and Liberty After Cancer 56863 2Ellis Island Event Celebrates Life and Liberty After Cancer 56863 3Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 56858 1Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 56858 2Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 56858 3Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid 56858 4Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes 4966 1Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes 4966 2
...gest and least studied freshwater turtles has been...hat the threatened species can be saved from extin...l (CI), World Wildlife Fund (WWF), the Cambodian F...Conservation Team captured and released an 11-kil... turtle (Pelochelys cantorii) during a survey in M...
... the Great Lakes and neighboring waterways is appr...wser, Cornell professor of aquatic animal medicine...hemorrhagic septicemia virus (VHSV), which causes ...tified in 19 species and poses a potential threat ... , "It’s pretty obvious this is an epidemic even i...
...s of healthy men decline as they get older. As sl...ge, objectively measured differences in the amount...level of testosterone in the morning, according to...ournal SLEEP. , The study, conducted by Plamen Pen... on 12 healthy men between the ages of 64 and 74. ...
Other Biology News:Rare soft-shell turtle, nesting ground found in Cambodia 2Rare soft-shell turtle, nesting ground found in Cambodia 3Cornell lab confirms deadly fish virus spreading to new species 2
GeneSnap from SYNGENE
E. coli Protein Sample, lyophilized, 2.7 mg from Bio-Rad
DISCOVERLIGHT 6XHIS ARRAY from Pierce Biotechnology, Inc.
...m provides excellent performance, reliability and ...ions, including washing of ELISAs, cellular assays...e, such as for PCR clean-up. The platforms outstan...r plate washers, with options including a process ...
Biology Products: